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Background: Constipation is a common condition, with prevalence after 65 years, is a major colorectal cancer risk factor.
Recent works have demonstrated advances in personalized, preventive nanomedicine, leading to the construction of new
materials and nanodrugs, in particular, nanocrystalline cerium dioxide (NCD), having strong antioxidative prebiotic effect.
The aim of our study was to investigate the influence of NCD on motor function of the stomach and colon in vivo and
contractive activity of smooth muscles in different year-old rats.
Methods: We included 80 rats: 3- (weight 130–160 g, n = 40) and 24-month old (weight 390–450 g, n = 40), divided
into four groups as follows: І—control group; rats of II–ІV groups were injected intragastrically one injection per day
during 10 days, 3 ml of water 3 ml/kg stabilizing solution, аnd 1 mmol/ml NCD, respectively. In all animals, we recorded
spontaneous and carbachol-stimulated (0.01 mg/kg) gastrointestinal tract motor activity. We used the index of motor
activity (IMA), expressed in cmH2O, for characterization of the motor function. We investigated smooth muscle contraction
by tenzometric method, studied the spontaneous and stimulated motility by ballonographic method.
Results: IMA reduced by 21.1 + 0.2% (p < 0.01) in the old rats of the control group compared with the young rats. A
10-day administration of NCD increased IMA in the stomach of young rats by 9.3% (р < 0.001) vs the control group. The
exposure of NCD increased the amplitude of contraction to 34.2 ± 5.4 mN (n = 10) in the stomach of old rats and
increased by 32.1 ± 2.4% vs the control group (p < 0.05). NCD did not influence acetylcholine (ACh) contractions in
the stomach of young rats; however, in the stomach of old rats, Vnr increased by 90 ± 15.2% (р < 0.001).
Conclusions: The index of motor activity is decreased in old rats. Nanocrystalline cerium dioxide increased the
index of motor activity in all groups of rats and also evoked a significant increase of colon contractions in old rats.
Keywords: Predictive, Preventive, Personalized medicine, Nanocrystalline cerium dioxide, Prokinetic, Smooth
muscle, Stomach, Colon, Gastrointestinal motility, Rat model, Gastrointestinal cancer prevention, CRC preventionOverview
Predictive, preventive and personalized medicine in
gastrointestinal motility and gastrointestinal cancer
prevention
In different countries, every third or fourth adult regu-
larly or occasionally suffers from constipation [1].* Correspondence: rostbubnov@gmail.com
2Zabolotny Institute of Microbiology and Virology, National Academy of
Sciences of Ukraine, Zabolotny Str., 154, 03680 Kyiv, Ukraine
4Clinical Hospital ‘Pheophania’ of State Affairs Department, Zabolotny Str., 21,
03680 Kyiv, Ukraine
Full list of author information is available at the end of the article
© 2015 Yefimenko et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Moreover, there is a sharp increase in their frequency
after 65 years [2]. It is known that constipation is a
major risk factor for colorectal cancer, because of the in-
creased level of carcinogenic metabolites in the colon
and increased time of contact metabolites with intestinal
mucosa [3].
The role of predictive, preventive and personalized
medicine for the human population to live longer, and
healthcare systems around the world is challenged to
find new ways to improve global health, dealing in par-
ticular with gastrointestinal cancer, colorectal cancertral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and clinicians collaborate closely in new developments
in a wide scope of complicated underlying mechanisms
of carcinogenesis in the vision of integrated medicine.
An actual problem of modern biomedicine is the de-
velopment of new prokinetics, such as majority of novel
drugs which have significant side effects [6,7]. Analysis
of existing motility promoters shows that the prebiotics
have least side effects. It is known that prebiotics acti-
vate motility and evacuation of the colon through the
formation of short-chain fatty acids [8].
Advances in nanoscience, nanotechnology and nano-
medicine lead to the construction of new materials and
devices for various scientific and therapeutic purposes
which are applicable in molecular diagnostics, nanodiag-
nostics and improvements in the discovery, design and
delivery of drugs, including nanopharmaceuticals.
Recent works have demonstrated that nanocrystalline
cerium dioxide (NCD) has prebiotic effect; however, its
prokinetic properties still were not studied.
Thus, the aim of our study was to investigate the influ-
ence of NCD on motor function of the stomach and
colon in vivo and contractive activity of smooth muscles
in different year-old rats.
Methods
The investigations were carried out on 80 rats maintained in
accordance with guidelines of Animal Ethical Research
Committee of Taras Shevchenko National University of Kyiv.
Protocol of Ethics Committee was N8 from 03.04.2014. Ani-
mals were divided into four groups: 3- (weight 130–160 g,
n = 40) and 24-month old (weight 390–450 g, n = 40). All
rats were deprived as follows: І—control group; ІІ—group
which were injected 3 ml of water (intragastrically, one in-
jection per day); ІІІ—rats which were injected 3 ml/kg sta-
bilizing solution (intragastrically, one injection per day);
аnd ІV—group of rats which were injected with NCD in a
dose 1 mmol/ml (intragastrically, one injection per day).
All drugs were administrating during 10 days.
Rats maintained on hunger with free access to water
for 12 h. Motor activity of the stomach and colon was
registered by ballonographic method in rats under ur-
ethane anesthesia (Sigma, USA) (1.1 g/kg, intraperito-
neally (i/p) [9,10]. Tracheotomy was performed. An
intragastric and colon balloon created from thin latex
rubber connected with plastic tubing was introduced
into the stomach and colon. In young animals, the bal-
loons were filled with 1 and 0.5 ml warm water (37°C)
accordingly. In old rats—1.5 and 0.7 ml, respectively.
This volume range was determined to be the level re-
quired to induce an intragastric and intracolon pressure
of 10–11 cmH2O. Spontaneous motor activity during
120 min of the animals of all groups after the 20-min
period was recorded. Afterwards, it was injected withstandard stimulant of motility carbachol (0.01 mg/kg, i/p,
Sigma, USA) and carried out further record. We used the
index of motor activity (IMA) for characterization of the
motor function of the gastrointestinal tract. IMA was
expressed in cmH2O.
The investigation of smooth muscle contraction of the
stomach and colon was performed according to the
method described in [11]. In the experiment, we used cir-
cular smooth muscle strips (medium size—2 × 10 mm),
cleaned of mucosa, which were placed in a chamber with
flowing Krebs solution of 5 ml (flow rate—5 ml/min).
Strips gave passive tension (10 mN) and left for 1 h. The
contractile activity was studied in isometric mode using
force sensors. Signals were recorded using an electric po-
tentiometer N339 (Russia). We selected classic stimulants:
hyperpotassium isotonic solution (HPS) and acetylcholine
(ACh). Analysis of contractile responses of smooth muscle
preparations were carried out according to the method
described in the article [11]. This method is based on the
transformation phase reduction and relaxation that are S-
shaped curves and can be mathematically described by the
general formula:
f ¼ f m
τn
τn þ tn
where f is the instantaneous (at time t) force, fm is the
maximum force, τ is the characteristic time (numerically
equal to the time at which there is half the maximum
value of the force ½ fm) and n is the logarithmic coeffi-
cient slope of mechanical kinetics curve.
The method involves linearization of phase relaxation of
mechanical kinetic curve in the coordinates {ln[(fm − f)/f];
ln t}, where fm is the value of the maximum power of con-
traction. Time, which is achieved fm, taken initial phase re-
laxation reference point t = 0; current value of time t
corresponds to the value of the instantaneous force f.
From the linearized curve, we determined kinetic parame-
ters: ln is the segment that cuts on the x-axis line drawn
through the experimental points and an empirical param-
eter n is the slope of the line that describes the steepness
dependence f (t). Kinetic value meaning of the characteris-
tic time of relaxation phase τ, that is, the time during
which the mechanical muscle tension decreases to a
level ½fm. The main kinetic characteristic of the process
of relaxation is maximum speed of the process. This
method allows to calculate the amplitude-independent
index-normalized maximum relaxation rate.
We used the following indicators of contractile activity
of smooth muscle preparations cuts: amplitude, ratio
phase and tonic components, phase contraction (Vnc)
and relaxation (Vnr) of maximal normality velocity.
NCD synthesized by methodology [12] in Zabolotny
Institute of Microbiology and Virology [13].
Figure 2 Index of motor activity of colon 3-month-old (І) and
24-month-old rats (ІІ). M+ SD, n= 10, ***р < 0.001, 24-month-old rats
compared with 3-month-old rats; ##р< 0.01, compared with the corre-
sponding control groups of rats, &&p< 0.01, respectively, to carbachol.
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W-test. All results are expressed as the M± SD of n values.
Statistical comparisons between groups were conducted
using Student’s t-test for unpaired data. Statistical signifi-
cance was set at р < 0.05 [14].
Results
In vivo studies of spontaneous gastric motility have
shown that IMA was reduced by 21.1 ± 0.2% (p < 0.01) in
old rats of the control group compared with the young
rats. A 10-day administration of NCD increased IMA in
the stomach of young rats by 9.3% (р < 0.001) relatively
to the control group (Figure 1).
Introduction of NCD also increased the motor activity
of the stomach of old rats: IMA increased by 19.8 ± 0.3%
(p < 0.001). Thus, the effect of strengthening of IMA by
NCD was almost twice higher in the old rats than in the
young. In old rats, NCD almost restored the value of
IMA targets of young animals (Figure 2).
The introduction of carbachol to young rats caused a
marked motor response in the stomach. IMA under carba-
chol action was driven by 34.2 ± 0.4% more than in terms
of spontaneous motility. IMA was lower by 14.6 ± 0.1%
(p < 0.01) in response to carbachol in the old rats thanFigure 1 A typical record of motor activity of the stomach in
rats. (A) Three-month rat; (B) 24-month rat; (C) 24-month rat after
10-day administration of nanocrystalline cerium dioxide; introduction
of carbachol at a dose of 0.01 mg/kg, ip.in the young. IMA increased after the 10-day administra-
tion of NCD in rats of both age groups. In young rats, IMA
increased by 8.2 ± 0.08% (p < 0.05) in old—14.5 ± 0.2%
(p < 0.05) (Figure 2). Thus, NCD amplified the effect of
carbachol in young and old rats.
In rats 24 months of age, IMA was 14.1 ± 0.3% (p < 0.001)
lower in the colon relative to the control group of young
rats. The 10-day introduction of NCD increased IMA by
13.4 ± 0.09% (p < 0.001) and 14.3 ± 0.1% (p < 0.001) in
young and old rats, respectively, compared with the corre-
sponding control groups (Figure 3).
Motor function of the digestive tract decreases with
age. In the old rats, the response to carbachol was also
weaker than in the young. NCD affect both basal and
stimulated motility in the stomach and colon. NCD re-
stored the indicators of motor activity in old rats to tar-
gets of young animals (Figure 4).
The studies on gastric smooth muscle preparations
showed that HPS-caused contraction characterized by
an average amplitude was 18.6 ± 11.7 mN, and the ratio
of phase and tonic components was 3.2 ± 3.5% (n = 10).
Aging did not cause changes in these parameters. Func-
tional activity of HPS-induced contractions of smooth
muscles of the stomach in a group of old rats underwent
no significant changes compared with those of young
animals, but tended to decrease (Table 1).
The 10-day administration of NCD increased the ratio
of phase and tonic components by 21.9 ± 1.1% (p < 0.05)
in the stomach of young rats. All other parameters,
NCD had no statistically significant effect.
Figure 3 A typical record of motor activity of the colon in rats.
(A) 3-month rat; (B) 24-month rat; (C) 24-month rat after 10-day
administration of nanocrystalline cerium dioxide; introduction of
carbachol at a dose of 0.01 mg/kg, ip.
Table 1 Indicators of HPS-induced contractions of stomach
smooth muscles in rats (n = 10)
Parameter 3-month-old rats 24-month-old rats
Amplitude (mN) 18.6 ± 7.8 25.9 ± 4.8
Tonic/phase components (%) 3.2 ± 3.5 4.5 ± 3.5
Velocity of contraction (Vnс)
(min−1)
2.1 ± 0.8 1.8 ± 0.2
Velocity of relaxation (Vnr)
(min−1)
0.74 ± 0.2 0.57 ± 0.1
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traction to 34.2 ± 5.4 mN (n = 10) in the stomach of old
rats, which corresponded to an increase by 32.1 ± 2.4%
compared with the control group (p < 0.05). The value of
the phase and tonic components in old rats increased to
10.0 ± 3.8% after the actions of the NCD, which was more
than 122 ± 7.9%, compared to young rats (p < 0.01). The
kinetic parameters of HPS-induced contractions statisti-
cally significantly increased under action of NCD in the
stomach of old rats. The rate of development of contract-
ile responses (Vnc) increased by 138.8 ± 11.2% (p < 0.01),
and the rate of phase relaxation (Vnr) by 128.1 ± 10.8%
(p < 0.01) (Figure 5).
ACh-induced contractions had amplitude 9.6 ± 3.8 mN
(n = 10) in young rats, but in old, it was 39.7 ± 4.1 mNFigure 4 Index of motor activity of colon 3-month-old (І) and
24-month-old rats (ІІ). M+ SD, n = 10, ***р < 0.001, 24-month-old
rats compared with 3-months of age rats; ##р < 0.01, compared with
the corresponding control groups of rats; &&p < 0.01, respectively,
to carbachol.(n = 10), which was higher by 313% (р < 0.001). The
value of the phase and tonic components had a tendency
to increase with age from 34.5 ± 12.8% to 49.4 ± 12.7%
(p > 0.05) (n = 10). Vnс of АCh-induced contractions had
no difference between the young and old rats in the stom-
ach. But Vnr decreased with age by 57 ± 8.6% (р < 0.05)
(Table 2).
NCD did not influence ACh contractions in the stom-
ach of young rats; however, in the stomach of old rats,
Vnr increased by 90 ± 15.2% (р < 0.001) (Figure 3). All
other parameters had no significance.
Contractile activity of HPS-stimulated contraction is
caused by Ca2+ ions which enter the smooth muscle
cells through potential-induced Ca2+-channel L-type
[13]. We assume that the mechanism of effects of NCD
in the stomach is mediated through the Ca2+ ions, due
to all indicators of HPS-induced contractions that were
growing after the 10-day administration of NCD in both
age groups and were not the changes of Ax-induced
contractions (except the phase of relaxation).
The investigation of parameters of motor activity of
the colon showed that HPS-induced contraction of
smooth muscles of young animals characterized by theFigure 5 The influence of nanocrystalline cerium dioxide (NCD)
on phase of contraction and phase of relaxation of HPS and
ACh-induced contractions. M± SD, n = 10, **р < 0.01 compared
with the corresponding control groups.
Table 2 Parameters of АCh-induced contractions of smooth
muscles of stomach in rats (n = 10)
Parameter 3-month-old rats 24-month-old rats
Amplitude (mN) 9.6 ± 3.8 39.7 ± 4.1**
Tonic/phase components (%) 34.5 ± 12.8 49.4 ± 12.7
Velocity of contraction (Vnс)
(min−1)
1.9 ± 0.7 1.3 ± 0.5
Velocity of relaxation (Vnr)
(min−1)
0.49 ± 0.3 0.21 ± 0.1*
*р < 0.05, **р < 0.001, compared with the control group of 3-month-old rats.
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phase and tonic components of the contractions was
12.3 ± 8.2%. In the case of the colon, smooth muscle of
old rats HPS-amplitude contractions remained close to
young animals (10.8 ± 5.1 mN, n= 10), and the ratio of
phase and tonic components tended to decrease (7.9 ± 4.1%,
n = 10, p > 0.05).
The applied kinetic analysis showed that with age, the
phase of reduction decreased by 47.8 ± 7.4% (p < 0.01),
and phase relaxation by 81.1 ± 13.2% (p < 0.01) (Figure 6).
These data indicate disrupted Ca2+ entry to the smooth
muscle cells through Ca2+-channel L-type in the colon of
rats with age. The proof of our assumptions is literature
data, which found that with reduced age, the level of intra-
cellular calcium in smooth muscle cells of the colon [15]
and acetylcholine release reduced by 50% in electrically
stimulated preparations of the colon [16]. In addition, re-
searchers found that K+ and Ca2+ currents through appro-
priate channels reduced in the smooth muscle cells of the
colon of old rats that influence the onset reduction [17].
NCD administration during 10 days did not cause the
changes in indicators of HPS-induced contractions of
smooth muscle of the colon in young rats. Whilst in the
old rats, the amplitude increased from 11.5 to 37.9 mNFigure 6 The changes of phase of contraction and phase of
relaxation of HPS-induced contractions with age. M± SD,
n = 10, **р < 0.01.(n = 10), which was more than 350% (p < 0.001). The
value of phase and tonic components of HPS-activated
contraction was 12.58 ± 4.95% (n = 10), which was more by
59.5 ± 9.1% (p < 0.05) in the case of control animals. In the
group of old rats, Vnc and Vnr increased by 166.8 ± 21.4%
and 644 ± 33.6%, respectively (p < 0.001) (Figure 7).
In the control group, an amplitude averaged 8.7 ± 2.2
mN (n = 10), and the ratio of phase and tonic compo-
nents were 24.6 ± 8.9% (n = 10) of ACh-induced contrac-
tions of smooth muscle of the colon in young rats. With
age, the amplitude of ACh smooth muscle contractions
of the colon increased to 15.6 ± 10.2 mN (n = 10), but
the ratio of phase and tonic components of the contract-
ile response decreased to 10.9 ± 0.7% (n = 10). These data
coincide with studies where it was shown that ACh in-
creased the strength of contractions in the colon of
young and old rats [18]. In old rats, kinetic characteris-
tics of ACh contractions remained similar to the data
obtained from the intestine of young animals.
The 10-day NCD administration caused the changes of
the parameter of ACh-induced contractions. In young rats,
the amplitude of ACh contractions increased by 177 ± 23.6%
(p < 0.001). The value of the phase and tonic components of
the contractile responses also increased by 30.9 ± 6.8%
(p < 0.05). In old rats, these values tended to increase.
Namely, the amplitude Ax-induced contractions increased
from 15.5 ± 10.2 to 16.9 ± 4.3 mN (n = 10) (p > 0.05), and
the ratio of phase and tonic components by 79 ± 7.6%
(p < 0.05). Since the phase ratio and tonic components
ACh contractions is an indicator of the efficiency of the
activation signal via muscarinic acetylcholine receptors
[19], our results suggest efficiency improvements activa-
tion of the signal after exposure of the NCD.
Kinetic parameters also undergo changes. Speed of the
contraction increased by 17 ± 4.3% and 34.3 ± 3.6% (n = 10),Figure 7 The influence of NCD on phase of contraction and phase
of relaxation of HPS-induced contractions in old rats. M± SD,
n = 10, **р < 0.01.
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old rats (Figure 8). However, no statistically significant
changes occur in the phase of relaxation of ACh-induced
contractions under action NDC.Discussion
Thus, NCD increased IMA of spontaneous and stimulated
motility in rats of both age groups in vivo. In smooth
muscle preparations, NCD affect parameters of HPS-
induced contractions in both age groups and the phase of
relaxation of ACh-induced contractions in old rats. In
view of this, we can say that the mechanism of NCD is
caused by Ca2+ ions which enter to the smooth muscle
cells through potential-induced Ca2+-channel L-type in
the stomach.
In old rats, a significant strength of the contractions
under action of NCD of the colon, activated by
depolarization of the plasma membrane, was observed.
Since Ca2+ ions that enter through potential-induced
L-type myocyte Ca2+-channel make the main contribution
to the generation of these cuts in the smooth muscles of
the gastrointestinal tract, it can be assumed that they are
one of the possible effector units under the action of NCD.
It should be noted as a significant acceleration of the
process of relaxation of hyperpotassium contraction in a
group of old rats that received NDC. It can be associated
with a number of cellular processes; in particular, this effect
may indicate activation of Ca2+ pumping from myoplasma
after excitement (possible effector proteins—Ca2+-pump
plasma membrane and/or the sarcoplasmic reticulum and
the Na+, Ca2+ exchanger). We cannot discard the effect of
NCD through the activation signal of muscarinic acetyl-
choline receptors as NCD increased parameters of ACh
contractions. Thus, NCD mediates its effects through
multiple effector units in the colon.Figure 8 The influence of NCD on phase of contraction of
ACh-induced contractions in young (I) and old (II) rats. M± SD,
n = 10, *р < 0.05.NCD may potentially act through the muscle, neurons
and amine precursor uptake and decarboxylation
(APUD) cell. Antioxidative actions of nanoceria on mo-
lecular and subcellular level are the potential clues for
understanding the mechanism of cancerogenesis.
For this reason, multiparameter study of colon motility
gives a new insight to digestive cancer pathogenesis under-
standing, modeling and development of personalized treat-
ment, and in the field of stress, visceral pain, vasospasm,
physical activity and nutrition within the integrated concept
of predictive, preventive and personalized medicine (PPPM).
Nanotechnologies—the challenge for advanced diagnosis,
treatment and prevention
Pharmacological, pharmaceutical and toxicological aspects
of the application of nanoparticles in biomedical purposes
still remain poorly understood. The application of nano-
particles allowing the combination of therapy and diagno-
sis, known as theranostic, has received increasing attention
in biomedicine [12,13,20], whilst oxidative stress has been
postulated as one of the main physiopathological hallmarks
of most of chronic diseases.
The application of nanoceria under conditions of involv-
ing oxidative stress can reduce/remove its damaging ef-
fects, thus providing protection to the organism from
adverse environmental factors: UV irradiation, viral, bac-
terial, fungal lesions induced toxic effects and pathological
conditions associated with aging. Nanoparticles of cerium
dioxide, considering its UV-shielding effect, antiviral, anti-
bacterial, antifungal activity, cardioprotective, neuro-
trophic, hepato- and nephroprotective, and anti-aging
effect, have potential for various biomedical applications
[12,13,20]. Treatment with nanoceria has supplementary
perspectives in gynecology and reproductive medicine
and also in women with hormone-associated obesity
which results from the increase in the number of oocytes
in follicles, increase in the number of oocytes at meta-
phase I and metaphase II, increase in the number of living
granulosa cells, and decrease in the number of necrotic
and apoptotic cells [13]. Musculotropic action of gold
nanoparticles [21,22] was reported as strong agents against
oxidative damage having anti-aging activity. Cerium
dioxide-based nanomaterials are also very promising in
cancer theranostics. Due to their unique properties, CeO2
nanoparticles are already used as a means of drug delivery
to the tumor site and as a diagnostic tool (either alone or
as part of the existing compositions), and as a means of
cancer treatment [12,13,20].
Gut microbiota and motility, obesity, vasospasm and
congestion in integrated PPPM vision for management of
digestive disorders
The gut microbiota can be considered an extension of the
self and, together with the genetic makeup, determines
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[23]. Strachan [24] described the hygiene hypothesis that
refers to an originally associated reduced microbial con-
tact to microbes in early life and is suggested to be one of
the main mechanisms to account for the increasing preva-
lence of allergic diseases over the past few decades. Today,
reduced microbial exposures (and the rise in allergic con-
ditions) have been attributed to Western lifestyle factors
such as diet, antibiotic use, vaccinations, reduced house-
hold size and improved hygiene [24]. The probiotic bac-
teria have been widely suggested to affect obesity and
metabolic disorders [25].
Endothelial dysfunction (ED) is an important risk fac-
tor that impairs blood flow controls in various organs.
Obesity impairs microvascular function in several ways.
ED results from an imbalance between nitric oxide (NO)
and endothelin (EDN), being the regulators of vascular
function. ED is associated with decreased NO produc-
tion due to impaired endothelial NO synthase activity
and expression, and increased production of superoxide
anion and the endogenous NOS inhibitor ADMA, to-
gether with increased vasoconstrictor factors, such as
endothelin-1 and sympathetic nerve activation [26].
Genetic variants in NO synthase and EDN isoforms and
its receptors (EDNRA and EDNRB) appear to account for
important components of the variance in ED, particularly
when concurrent risk factors such as obesity exist. Ana-
lysis of genotype-phenotype interactions is critical for the
formulation of the potentially altering predisposition to
cardiovascular diseases [27]. NO synthase and endothelin
genes are related with many diseases, namely, asthma [28]
and renal failure [29], that make them the potential bio-
markers of numeral obesity collateral pathologies.
Meyer et al. found that in the aorta of obese mice, peri-
vascular adipose potentiates vascular contractility to sero-
tonin and phenylephrine, indicating the activity of a factor
generated by perivascular adipose, which was designated as
‘adipose-derived contracting factor’ (ADCF) [30]. Inhibition
of cyclooxygenase (COX) fully prevented the ADCF-
mediated contractions, whereas COX-1 or COX-2-
selective inhibition was only partially effective. By contrast,
inhibition of superoxide anions, NO synthase, or endothelin
receptors had no effect on ADCF activity [31].
Congestive mesenteric [32] and/or pelvic syndromes
(ovarian vein reflux) [31] are the condition characterized
by the presence of venous congestion and varicose veins
in the mesenteric and pelvic region, and play important
role for dysregulation of intestinal and systemic microcir-
culation mechanisms leading to ED and have potential risk
for the development of many vascular and hormonal disor-
ders. In obese individuals, the mixed meal drink decreases
the baseline skin perfusion and causes acetylcholine-
mediated vasodilation, but has no effect on the capillary
density. Obese individuals had impaired acetylcholine-mediated vasodilation after meal ingestion. The latter find-
ings are consistent with impaired postprandial microvascu-
lar function in obesity [33,34].
Peripheral microcirculation assessment might be consid-
ered to support a supplementary information for obese pa-
tients particularly for vasospasm assessment [35], including
laboratory biomarkers and capillaroscopy [36]; Doppler
techniques for assessment of vascular responses following
cuff-induced arterial occlusion allow determinations of the
kinetics of post-ischemic reperfusion and provides an accur-
ate reporter of NO-mediated physiological recruitment [27].
Pathways between skeletal muscle spasticity and with
visceral, myofascial pain [36] and also with Flammer
syndrome [37] might give interesting pathogenesis clues
to understanding this psyche-intestine-circulation-pain
interaction as a whole.
CNS and enteric neuroregulation of digestive motility—insight
for carcinogenesis—and challenge for PPPM
The digestive system is innervated through its connec-
tions with the central nervous system (CNS) and by the
enteric nervous system (ENS) within the wall of the
gastrointestinal tract [38]. The ENS is located within the
wall of the gastrointestinal tract and responsible for its
physiological functions such as secretion, blood flow and
motility [39,40], working in concert with CNS reflex and
command centres and with neural pathways that pass
through sympathetic ganglia to control digestive func-
tion have a high affinity for the peripheral nervous sys-
tem (PNS), may also react within the ENS, which is the
largest and most complex subdivision of the PNS [38].
Damage to enteric neurons, or changes in their electro-
physiological properties, results in altered and deficient
physiological functions of the gut which has been dem-
onstrated in studies of intestinal inflammation [41,42].
Deficient physiological functions have been demon-
strated as a result of damage to neurons in the ENS of
rats following long-term cisplatin administration [39,41].
Interaction of neural tissue motility and carcinogenesis
was studied in several papers of Ceyhan et al. [43-46] and
the ‘neural remodeling’ was described in carcinogenesis in
the pancreas that implies that the local activity of the
autonomic nervous system may be subject to an inhib-
ition, which is why studies on the effect of (autonomic)
neurotransmitters on cancer cells and in murine pancre-
atic cancer models which do not reflect pancreatic neuro-
plasticity should be interpreted and translated cautiously.
Authors assumed that:
Firstly, neurotransmitters can directly induce cell
migration or regulate other parts of the metastasic
multi-step process. Secondly, tumor cells can use nerve
fibers as routes for invasion and emigration from the
primary tumors.
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dle, and there are only few methods established on this.
One of the most advanced methods is probably that
used by Ayala et al. who co-cultured dorsal root ganglia
from mice with tumor cells [47,48].
Nerves in cancerogenesis were reported as a rich
source of neurotrophic factors like nerve growth factor
(NGF), glial-cell-derived neurotrophic factor (GDNF),
artemin; of neuronal chemokines like fractalkine; and of
autonomic neurotransmitters like norepinephrine which
can all enhance the invasiveness of cancer cells via matrix-
metalloproteinase (MMP) upregulation, trigger neural
invasion (NI) and activate pro-survival signaling path-
ways [43].
These data of evidence supports a longstanding hypoth-
esis that chronic stress can influence tumor growth and
progression [44].
Neuroendocrine, APUD cells signaling, serotonin,
substance P
Neuroendocrine, APUD cells signaling and serotonin
are important and not sufficiently studied mechanisms
for number of pathologies of different localization, and
link amongst series of pathological processes as obesity
gut motility, cancer, etc. Serotonin is a primal signaling
molecule conserved across phyla that is implicated in
the control of energy balance [49-52]. Observations sug-
gest that constitutive gastrointestinal motility depends
more on neuronal than EC cell serotonin; moreover, se-
rotonergic neurons promote development/survival of
some classes of late-born enteric neurons, including
dopaminergic neurons, which appear to innervate and
activate in the adult ENS. As obesity increases peripheral
serotonin, the inhibition of serotonin signaling or its
synthesis in adipose tissue may be an effective treatment
for obesity and its comorbidities [53]. Crane et al. [53]
have found that genetic or chemical inhibition of Tph1
protects or reverses the development of HFD-induced
obesity and dysglycemia via activation of UCP1-mediated
thermogenesis. Thus, inhibiting Tph1-derived serotonin
may be effective in reversing obesity and related clinical
disorders such as NAFLD and type 2 diabetes.
Still interesting as a substrate for research and poten-
tial biomarker remains substance P, involved in nocicep-
tion, and transmitting information about tissue damage
from peripheral receptors to the central nervous system
to be converted to the sensation of pain [54]. It has been
theorized that it plays a part in fibromyalgia [55,56] and
showed prokinetic properties, whilst was found to se-
crete serotonin as well as substance P and neurotensin
by intestinal protozoa [57]. Substance P activates colonic
motility via a direct action on colonic muscles over the
whole colonic length and by simultaneous activation of
neural cholinergic excitatory pathways in the middle anddistal of noncholinergic excitatory pathways in the prox-
imal colonic segment, and by activation of nitric oxide-
dependent inhibitory neural pathways [58]. Substance P
also has effects as a potent vasodilator, inducing vaso-
dilatation is dependent on nitric oxide release [59].
Potential advantages over existing laxatives, translation
and implementation
Chronic idiopathic constipation, being a common func-
tional disorder of the gastrointestinal tract, is a condition
difficult to treat. Many of the novel treatment techniques
in spite of showing their effectiveness still lack rigorous
scientific support (level I evidence), and that means that
at least randomized controlled trials have been per-
formed and the treatment approach has been found to
be effective. However, today, many of the usual every
day practice treatments including using laxatives still are
not supported by level I evidence [60-69].
Despite the widespread use of laxatives by health pro-
fessionals to manage constipation, there has been a long
standing lack of evidence to support this practice. There
is little shared understanding between patients and pro-
fessionals about ‘normal’ bowel function with little con-
sensus in general practice of the optimum management
strategies for chronic constipation and the most effective
strategies to use. Chronic constipation still has not been
an agreed management target within national frame-
works [60]. Thus, in review by Gordon et al., polyethyl-
ene glycol preparations may increase the frequency of
bowel motions in constipated children. Polyethylene gly-
col was generally safe, with lower rates of minor side ef-
fects compared to other agents. Common side effects
included flatulence, abdominal pain, nausea, diarrhea
and headache. Common side effects with liquid paraffin
included abdominal pain, distention and watery stools.
There was no evidence to suggest that lactulose is su-
perior to the other agents studied, although there were
no trials comparing it to placebo [61]. Evidence for any
benefit of laxatives is conflicting [62], and there has been
no definitive summary of the evidence.
Thus, the use of laxatives still has a number of limita-
tions and side effects and problem to cumulate evidence.
Patient preferences and the absence of patient equi-
poise formed an enormous barrier to the recruitment of
patients in the implementation of the trial. Studies are
needed to investigate different methods of recruitment
within the constraints of current ethical guidelines on
‘opting in’ and to identify barriers and facilitators to re-
cruitment to complex trials in general. Patient prefer-
ence trials and natural cohort observational studies are
also needed to investigate the effectiveness or cost-
effectiveness of different laxatives and treatment strat-
egies in the management of chronic constipation [61].
The majority of patient-recruited trials were in an
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Ten trials compared one laxative agent with another.
The mean age of participants in these trials was esti-
mated at 77 years. Only one trial examined patients in
an outpatient setting; the other trials were carried out in
nursing homes or hospitals [63]. In addition, these stud-
ies were relatively short in duration, and so it is difficult
to assess the long-term effectiveness of these agents for
the treatment of constipation. Long-term effectiveness
assessment is essential, given the often chronic nature of
this problem to prove effectiveness over placebo control
for treatment to prevent one patient failing to respond
to therapy [64].
Considering the results of current research and series of
hypothetical issues, developed nanocrystalline cerium
dioxide-based prokinetic agents should have potential ad-
vantages compared to the existing laxatives on the market
being safe and biocompatible; have no (few—additional
studies necessary) side effects; acts on several chains on
pathogenesis; have harmonized multifactorial local and
systemic antioxidative action; potential preventive effects;
have prebiotic properties, may be used as food supplement
with probiotics and sophisticated personalized diets pro-
gramming; and are inexpensive.
Future research planning should focus on methods of
translating obtained data to human organism and should
initiate related research towards increasing level of evidence
for promising and effective treatments that are still not suf-
ficiently supported by evidence and adhere study protocols
to the PPP medicine, including 1) in vitro studies; 2) in vivo
studies in laboratory animals; 3) epidemiological studies; 4)
studies on human volunteers and patients with relevant
assessment of efficacy of each particular case.
High-quality basic research are needed (including mo-
lecular, immunohistochemical, preclinical imaging micro-
biology study); tests of safety and biocompatibility of the
product with development and standardization of a proto-
col to perform predictive modeling of the GI function
and prokinetic intervention; identification of the associa-
tions that are specific to the models and distinguish from
those that are specific for humans; and identification of
the associations that are common to humans and animal
models with focus on mechanism in elderly, carcinogen-
esis in order.
Clinical studies on volunteers and recruited patients
with sufficient methodological quality should include
psychoemotinal and physical assessment and statistical
issues that are associated with modifiable factors (nutri-
tion, physical activity, behavior, etc.), with caution due
to potential inaccuracies to avoid potential limitations
inherent to dietary research, constipation studies (as
intention-to-treat analysis, relevant long-term symptoms
assessment, placebo control, proper randomization, eth-
ical research sponsorship, etc.), and in strong adherencewith for development of sophisticated personalized diets
considering dietary modifications due to microbiota is-
sues, multiple dietary factors (like food, environmental
toxins) affecting on GI motility and individual health as
a whole; toxicity studies for constipation and detoxifica-
tion effect of NCD in particular. Afterwards, after rele-
vant legislation, registration and control procedures,
NCD-based products might be implemented as novel
treatments and prebiotic dietary supplement ensuring
the quality and truthful marketing.
Consolidation of the PPPM concept
The results of the study are potentially applicable for
creating products—food supplements, develop safe and
effective person-related treatments for constipation
beneficial for individual outcomes with particular appli-
cation in elderly, and on the other hand, be part of large
concept within interactome in order to suggest a healthy
lifestyle and sustainable well-being and aging, and also
to be a contribution to the understanding of issues of ir-
ritable bowel, inflammatory bowel disease (IBD) and vis-
ceral pain cancerogenesis.
Preventive medical approach
Translation of the obtained data on animal model to hu-
man organism may allow to consider diet correction
with nanoceria additives in particular in elderly against
constipation and related bowel diseases.
The results have a potential for preventions a wide
scope of bowel diseases and CRC and for promotion of
health in the integrated vision of interactome.
Personalized medical approach
Designing person-related smart physiologic low-dose
treatments as important impacts to personalized dietol-
ogy and is a challenge for medicine of future. Clinical
study is necessary for stratifications of potential re-
sponders to formulate clear personalized application.
Considering biosafety of ceria nanoparticles, the group
of potential patients (consumers) can be large.
Predictive medical approach
Developing the panel of bowel diseases assessment bio-
markers from the point of view of extensive vision in-
cluding gut-brain axis (GBA), intestine microbiota,
psyche, stress, emotions, pain, physical activity and mo-
lecular and cellular mechanisms is an important point.
Development and validation of questionnaires for diagno-
sis of motility disorders as irritable bowel syndrome, rele-
vant animal modeling using appropriate techniques as
in vivo imaging (ultrasound, endoscopy, etc) and methods
of translating obtained data to human organism should
initiate related research towards study of CNS and the
ENS within the wall of the gastrointestinal tract and
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environment and be a source of potential biomarkers.
Expert recommendations
With the concluding points, we can formulate the following
proposals (expert recommendations):
 For the European Union (EU): create an
international research project to study the
biomedical effects of nanoceria offer the prospect of
its use as a UV protectant, a drug with antiviral,
antibacterial and antifungal activity, as well as means
capable of reducing the level of oxidative stress in
diverse tissues of human body.
 Initiate discussion to suggest project for preventions
a wide scope of bowel diseases and CRC and for
promotion of health in the integrated vision of
interactome.
Conclusions
1. The index of motor activity decreases in the
stomach and colon in rats with age.
2. The amplitude, the phase of contraction and phase
relaxation of the contractions caused by
hyperpotassium solution decreased in smooth
muscle of the colon in old rats.
3. The administration of nanocrystalline cerium
dioxide increased index of motor activity of
spontaneous and stimulated motility of the stomach
and colon in rats of both age.
4. In old rats, nanocrystalline cerium dioxide evoked a
significant increase the amplitude, phase contraction
and reduction of contractions of the colon, activated
by depolarization of the plasma membrane in old
rats.
5. Nanocrystalline cerium dioxide increased the
amplitude, phase contraction, phase ratio and tonic
components of the acetylcholine contractile
responses of smooth muscles of the colon in old
rats.
6. Obtained results can be the basis for creating a new
laxatives based on nanocrystalline cerium dioxide.
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